
ORIGINAL PAPER

**INTRANASAL CORTICOSTEROIDS OF THE NEW
GENERATION IN THE THERAPY OF THE CHILDREN
WITH ALLERGIC RHINITIS**

ABSTRACT**Snežana SANKOVIĆ-BABIĆ
Rade KOSANOVIĆ***ENT Clinic - KBC Zvezdara,
Belgrade, Serbia**Received: 11.05.2010**Accepted: 14.11.2010***Correspondence to:***Doc.dr. Snezana Sankovic-Babic
ORL Klinika KBC Zvezdara,
Prevska 31, Belgrade
Serbia**Phone: +381 11 2417 574**Fax: +381 11 2412 394**Email: ssankovicbabic97@gmail.com*

According to a recent epidemiological studies the average rate of prevalence of allergic rhinitis (AR) in children, in USA is between 20- 40% and in Western Europe up to 20%. The disease most frequently appeared in children age 4 to 11. In this study authors analysed the results of the recent studies according to the literature data about the efficacy and safety of the intranasal corticosteroids in children with allergic rhinitis. These drugs as well as antihistamines and decongestants, are the first line therapy choice in allergic rhinitis. According to the numerous experimental and clinical studies, intranasal corticosteroids of the new generation decrease the intensity of allergic inflammation by induction of apoptosis of eosinophils and by decreased expression of intercellular adhesion molecules (ICAM) and proinflammatory mediators as TNF-alpha, IL-8, IL-4, IL-5. All studies in children showed no significant bioavailability and no effect on plasma cortisol level in therapy with new generation of intranasal corticosteroids. The leading symptom of allergic rhinitis, nasal congestion, was markedly reduced. Intranasal corticosteroids decrease the intensity of symptoms in comorbid diseases in children as sinusitis, secretory otitis media and asthma attacks. The local adverse effects of intranasal corticosteroids such as irritability of nasal mucosa, dryness of the nose and mouth, headache and epistaxis are rare. The results of recent studies showed that intranasal corticosteroids of the new generations have high safety profile and are recommended as the first line therapy choice in children with moderate to severe type of persistent allergic rhinitis.

Key words: *allergic rhinitis, children, intranasal corticosteroids*

INTRODUCTION

Allergic rhinitis is IgE mediated allergic inflammation of the nasal mucosa.¹ According to a recent epidemiological studies of allergic rhinitis in children, the incidence of the disease ranged between 20 to 40% in USA and above 20% in Western Europe.^{2,3} The peak of incidence was diagnosed in children age 4 to 11 year.^{2,3} The major clinical signs are nasal congestion, rhinorrhea, itching, postnasal drip and cough. These complaints can detriment the quality of life decreasing the learning ability and attention and in the most severe cases causing sleep disturbances in children.^{1,2,3,4}

Typical clinical findings are: pale nasal mucosa with swollen turbinates, clear to white nasal secretions, and conjunctival injection or lacrimation. The diagnosis can be established through a focused medical history and physical examination with correlation of the patient's symptoms to positive results on skin-prick tests, IgE plasma concentration and eosinophils number in nasal smear. Comorbidities of allergic rhinitis include sinusitis, eustachian tube dysfunction with development of secretory otitis media, aggravation of asthma, and an increased likelihood of developing asthma due to increased airway inflammation and hyperresponsiveness.^{6,9}

The clinical symptoms of allergic rhinitis are the result of complex pathophysiology of allergic inflammation and dysfunction of respiratory mucosa of upper and lower airways. The most recent studies suggested the concept of the unified airway allergic disease. Allergic rhinitis is one of modalities of this clinical condition and could exist alone or being accompanied by other modalities known as comorbidities (asthma, secretory otitis media, sinusitis). It is well known that allergic rhinitis often coexisted with asthma, allergic dermatitis and conjunctivitis and in that way it can represent atopic constitution of the patient.^{6,7}

Rhinosinusitis was diagnosed in over 70% of the patients with allergic rhinitis. According to some clinical CT studies of paranasal sinuses in allergic rhinitis, 77% pathological changes of ostiomeatal complex were found.⁸ Persistent allergic inflammation cause the dysfunction of mucociliary clearance and oedema of the sinonasal mucosa. Nasal congestion, postnasal secretion, cough and headache are the major signs of the rhinosinusitis. Frequently, allergic inflammation of the sinuses were accompanied by exacerbation of the acute viral or bacterial inflammation.⁹ Rhinosinusitis was more frequently diagnosed in persistent allergic rhinitis. Huang et al. pointed out that in the clinical studies of 251 children with persistent allergic rhinitis, rhinosinusitis was diagnosed in 46% but only in 4 % in the group of children with allergic rhinitis of the seasonal type.¹⁰

Secretory otitis media (SOM) is a disease that occurs in pre-school children clinically manifested as the presence of fluid behind an intact eardrum with conductive deafness, but no signs of acute inflammation. The disease is caused by different etiological factors: (morphological effects – cleft palate, craniofacial anomalies, genetic defects of ciliary epithelia (Cartagen's syndrome), gastroesophageal reflux, frequent infections of the upper respiratory tract with hypertrophy of the lymph tissue of the nasopharynx, hypertrophy of tubular tonsils, allergies, environmental factors – malnutrition and children fed only with synthetic baby food, as well as living in an environment full of dust, mold and cigarette smoke. Atopic constitution is a risk factor that four times more often causes the occurrence of SOM in children with allergies than in children that are not allergic.^{11,12,13} Eosinophil cationic protein (ECP), mastocyte tryptase and myeloperoxidase of neutrophils have been identified in high concentrations in secretion and mucous membrane of the middle ear in children with allergy and secretory otitis.^{12,13} Stimulation of the respiratory mucous membrane of the upper respiratory tract with an allergen and/or histamine leads to dysfunction of the Eustachian tube in more than 70 % of patients with allergic rhinitis. According to recent clinical studies the

incidence of SOM in children with allergic rhinitis is between 40 to 60%.¹³

Allergic rhinitis is a risk factor for development of asthma. More than 40% of patients who suffer from allergic rhinitis have asthma. Persistent type of allergic rhinitis more frequently cause asthma attacks than seasonal type of rhinitis. Some studies claimed that more than 90% patients with asthma have had allergic rhinitis.¹⁴ In the patients with seasonal allergic rhinitis and asthma, worsening of the symptoms of asthma was observed during the pollen season.¹⁴ Some studies examined the bronchial mucosa in nonasthmatic patients with allergic rhinitis. The bronchial mucosa specimens showed a slight increase in the basement membrane thickness and a presence of eosinophilic inflammation. The increase in airway responsiveness was recorded by nasal provocation tests in nonasthmatic patients with allergic rhinitis during pollen season.¹⁴

Results of the experimental studies with nasal provocation allergen test (grass pollen) showed increased expression of intercellular adhesion molecules (ICAM) and increased number of eosinophils in nasal mucosa and nasal secretion and as well as in bronchial mucosa.¹⁴ Similar results were confirmed by the experimental studies with bronchoprovocation tests. After bronchoprovocation test with grass pollen, increased number of eosinophils and increased concentrations of IL 5 were recorded in bronchial and nasal mucosa. The recent recommendation by ARIA association suggested the simultaneous therapy of the asthma and rhinitis.⁶

Intranasal corticosteroids of the new generation (mometasone, fluticasone) (INCS) were recommended as the first line therapy in the treatment of the allergic rhinitis in children.^{14,15,16} The dilemma concerning the duration of the therapy is always present when therapist prescribe corticosteroid drugs. The ground reason for selection of intranasal corticosteroid is limited number of local adverse effect and the lack of the evidence about systemic adverse effect as confirmed by numerous clinical and experimental studies in last two decades.^{14,15,16,17}

The aim of this study was to analyse the clinical benefit of the use of intranasal corticosteroids of the newer generation in the children with allergic rhinitis according to a recent clinical studies.

INTRANASAL CORTICOSTEROIDS AND ALLERGIC INFLAMMATION OF THE NASAL MUCOSA

The mediators of the early and late phase of allergic

Table 1. The effects of intranasal corticosteroids in allergic inflammation of nasal mucosa^{19,20,21,23}

Mediator/cell	The effect on cellular expression or mediator concentration
Eosinophyls	Reduction in number and apoptosis
Expression of ICAM, VCAM	decreased
Concentrations of proinflammatory cytokines (TNF alpha, IL-8)	decreased
Concentrations of cytokines IL-4, IL-5	decreased
Concentrations of mastocyte triptase and eosinophyl cationic protein (ECP)	decreased

inflammation were frequently analysed in pathophysiology of allergic rhinitis. Increased permeability of the blood vessels, interstitial oedema of the nasal mucosa and dysfunction of the sensory nerve endings appeared within few hours after interaction of allergen and IgE antibodies. Dominant effect in early phase of allergic inflammation of the nasal mucosa was mastocytes and basophiles degranulation and increased concentration of histamine, prostaglandins, leukotriens, bradykinine and substance P. This phase last of 4 to 8 hours after allergen challenge.^{7,18,19} The activation of the immunocompetent cells is the crucial event in the late phase. Activated macrophages, mast cells, eosinophils, lymphoplasmocytes, basophils and neutrophils produce increased concentration of leukotienes, prostaglandins and Th 2 cytokines (IL- 4, IL- 10). Increased expression of the intercellular adhesive molecules (ICAM) on epithelial cells and endothelial cells can additionally enhance migration and activation of the immunocompetent acells. The final result is the amplification of the allergic inflammation of the sino-nasal mucosa.^{19,20}

The optimal pharmacotherapy of allergic rhinitis should maintain the reduction in number of the inflammatory cells and decrease the production of the mediators in nasal mucosa. The molecular effect of the intranasal corticosteroids in the inflammation of the nasal mucosa is still the subject of research studies. In vitro studies which followed the level of molecular interaction between intranasal corticosteroid drugs and human recombinant corticosteroid receptor showed that momethasone had the strongest receptor affinity as compared to other drugs like fluticasone or budesonide (momethasone-1235, fluticasone 813, budesonide258).²²

Clinical and immunohistochemical studies showed that local application of the newer generation of the intranasal corticosteroids results in apoptosis of the

eosinophyls. Decreased number of intraepithelial and subepithelial eosinophils in nasal mucosa specimens, as well as decreased number of basophils and lymphoplasmocytes was noticed in nasal mucosa after administration of the intranasal corticosteroids.^{20,21,23} As a consequence, the decreased concentration of mediators occurs such as decreased levels of tumor necrosis factor alpha (TNF alpha), interleukin 8 (IL 8), interleukins 4 and 5 (IL 4, IL 5) as well as decreased concentrations of mastocytes tryptase, eosinophilic cationic protein (ECP), leukotriens and prostaglandins. It was noticed that corticosteroids can inhibit the activation of nuclear factor kappa B (NF kappa B) which was recognized as one of the most important proinflammatory transcriptional factor in the process of allergic inflammation.²⁰

The decreased expression of the intercellular adhesion molecules (ICAM) and vascular adhesion molecules (VCAM) on the surface of the endothelial and epithelial cells of the nasal mucosa was noticed after nasal mucosa was exposed to intranasal corticosteroids (Table 1).^{19,21,23}

Minshal et al. studied mucosal biopsies of the nasal mucosa in 69 patients with persistent rhinitis before and one year after continuous administration of the momethasone furoate in the daily dose of 200 µg. Immunohistochemical analysis showed that prolonged administration of the momethasone did not cause atrophy of the nasal mucosa. Comparison between mucosal biopsy specimens showed decreased number of intraepithelial and subepithelial eosinophils, as well as increase in number of cylindrical cells of respiratory type one year after momethasone therapy. As conclusion, author emphasized that momethasone has important role in the restitution of nasal mucosa.²¹ Immunohistochemical studies of the nasal mucosa biopsies have not been studied so far in children with allergic rhinitis.

CLINICAL BENEFIT AND ADVERSE EFFECTS OF THE INTRANASAL CORTICOSTEROID THERAPY IN CHILDREN WITH ALLERGIC RHINITIS

According to a recent clinical studies the corticosteroids of the new generation (mometasone, fluticasone) can be very effective in reduction of nasal congestion, anterior and posterior nasal drip and cough.^{7,15,16,17} The crucial reason for the use of intranasal corticosteroids of the newer generation is local administration without systemic adverse effects. Systemic adverse effects of active corticosteroids are: osteoporosis, glaucoma, cataracts, adrenal suppression, and impaired growth in children. The newer intranasal corticosteroid (INCS) drugs have been found to have no adverse effects on growth and hypothalamic-pituitary-adrenal-axis function in children.^{16,17}

After administration of the first dose of INCS initial clinical signs occurred between 4 to 12 hours. Clinical studies showed that initial reduction of the nasal congestion occurred 5 hours after mometasone administration and reached complete reduction of nasal congestion 36 hours after in patients with seasonal allergic rhinitis. Mometasone was administered in the daily dose of 200 µg.²⁵ Significant decrease of total nasal symptom score was observed third day after INCS administration.²⁵ Efficacy studies performed in children with seasonal type of allergic rhinitis recommended as optimal daily dose of 100 µg during 2 weeks.^{15, 16,17}

In 544 children age 2 to 11 years with seasonal allergic rhinitis the reduction of total nasal score (congestion, itching, posterior and anterior nasal drip) was significantly reduced as pointed out by Meltzer. The therapy consisted of fluticasone given in daily dose of 110 µg during two weeks.²⁷ Intranasal corticosteroids of newer generation could be used as prophylactic therapy in patients with moderate to severe seasonal allergic rhinitis. In 61 patients age 12 to 57 years, Pitsios et al. were administered mometasone in single daily dose of 200 µg. According to the results of this study 78% of patients have had minimal symptoms of allergic rhinitis at the starting point of pollen season with daily total nasal score less than 1.4.²⁸ Similar studies have not been yet published in children with allergic rhinitis.

Therapy with INCS in severe forms of persistent allergic rhinitis was analysed in a few studies. Skoner et al. measured cortisol plasma level and growth index in 59 children age 4 to 10 years with persistent rhinitis. The patients were treated by fluticasone in daily dose of 200 µg during 14 days with wash out period of 14 days. Results of this study pointed out safety of this therapy schedule with no significant increase in plas-

ma cortisol level and no influence in growth index of treated patients.²⁹ Similar results were published by Schenkel et al. Study included 98 children with persistent allergic rhinitis age 3 to 9 years treated with mometasone in daily dose of 100 µg. The duration of the therapy was one year.³⁰ Galant et al. analysed the cortisol level during six week therapy in children age 2 to 3 years with persistent allergic rhinitis which were administered fluticasone in single daily dose of 100 µg. The results of this study showed no increase in daily plasma corticoid level, no growth disturbances and no pathological findings during ophthalmoscopy.³¹ The potential for systemic activity INCS might be explained by nasal epithelium absorption or by absorption through gastrointestinal tract. Low nasal and gastrointestinal absorption rate and fast first pass hepatic inactivation are important pharmacokinetic properties of INCS of newer generation. After oral administration the fraction of drugs which become bioavailable was measured for beclomethasone, fluticasone and mometasone. The bioavailability rate ranges from 41% to 11% for beclomethasone to less than 1% for mometasone and fluticasone.^{31,32} Some of the studies showed that beclomethasone dipropionate intranasal spray caused significant growth suppression of 0.9 cm after one year of the drug administration in doses of 168 mcg BID in children with allergic rhinitis.³²

Local adverse effects appeared in the interval between 5 to 10 % after intranasal administration of mometasone and fluticasone longer than 4 weeks. Studies that followed INCS administration in two weeks interval in children with seasonal allergic rhinitis reported local adverse effects in the frequency less than 2%.^{30,31,32,33}

Headache, burning nose, bad taste, somnolence or insomnia, sanguinolent nasal discharge or epistaxis are the local adverse effects that were most frequently reported. Vasoconstriction is the main pathophysiological mechanism that cause mucosal dryness and epistaxis after prolonged administration of INCS. The most severe complication as perforation of the nasal septum was rarely described in adult patients but there is no reports about that complication in children. Before the therapy has been started, parents should be given all information about adverse effects of INCS. If any of aforementioned adverse effects appeared parents must be informed to stop further administration of the INCS and to bring child to control examination. Daily doses that were recommended for pediatric population with allergic rhinitis are 100 µg up to 14 days. This therapy schedule was recommended as one with minimal or no local adverse effects at all.^{17,30,31,32,33} In the case of prolonged therapy with INCS, frequent control examinations were recommended, each 14 days. The therapy duration depends on

symptoms of the disease and it should be individually adjusted according to oscillation in intensity of symptom nasal score of AR. The results of recent studies showed that intranasal corticosteroids of the new generations have high safety profile and are recommended as the first-line therapy choice in children with all forms of allergic rhinitis especially in children with moderate to severe type of persistent allergic rhinitis.

REFERENCE

- Nathan RA. The burden of allergic rhinitis. *Allergy Asthma Proc* 2007;28(1):3-9. doi:10.2500/aap.2007.28.2934 PMID:17390749
- Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. *Eur Resp J* 2004;24:758-64. doi:10.1183/09031936.04.00013904 PMID:15516669
- Bachert C, Van Cauwenberge P, Olbrecht J, Van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. *Allergy* 2006, 61:693-8. doi:10.1111/j.1398-9995.2006.01054.x PMID:16677237
- S.Sanković-Babić. Intranasal corticosteroids in allergic rhinitis. *Medicus* 2007 (18), 4-6.
- Demoly P, Aïaert FA, Lecaesle M, Bousquet J. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma) *Allergy* 2003, 58:672-5. doi:10.1034/j.1398-9995.2003.t01-1-00202.x PMID:12823130
- Van Drunen, Meltzer E.O, Bachert C, Bousquet J, Fokkens WJ. Nasal allergies and beyond: a clinical review of the pharmacology, efficacy and safety of mometasone furoate. *Allergy* 2005, 60 (suppl 80):5-19. doi:10.1111/j.1398-9995.2005.00917.x PMID:15948774
- Piette V, Bousquet C, Kvedariene V, Dhivert-Donnadieu H, Creampette L, Senac JP. Sinus CT scans and mediator release in nasal secretion after challenge with cypress pollens. *Allergy* 2004, 59:863-8. doi:10.1111/j.1398-9995.2004.00509.x PMID:15230820
- Ciprandi G, Cirillo I, Kersy K, Marseglia GL, Caimmi D, Vizzaccaro A. Nasal obstruction is the key symptom in Hay fever patients. *Otolaryngol Head Neck Surg* 2005 (113) 429-35. doi:10.1016/j.otohns.2005.05.049 PMID:16143195
- Huang SW. The risk of sinusitis in children with allergic rhinitis. *Allergy Asthma Proc* 2000, 21:85-88. doi:10.2500/108854100778250905 PMID:10791108
- Skoner DP, Doyle WJ, Freeman P. Eustachian tube obstruction after histamine nasal provocation: a double blind study. *J Allergy Clin Immunol* 1987, 79:27-31. doi:10.1016/S0091-6749(87)80012-X
- Sankovic-Babic S, Atanaskovic-Markovic M, Kosanovic R. Allergy and secretory otitis media. *Acta Med Sal* 2008; 37 (2): 166-170
- Luong A, Roland PS. The link between allergic rhinitis and chronic otitis media with effusion in atopic patients. *Otolaryngol Clin North Am* 2008 (41):311-323. doi:10.1016/j.otc.2007.11.004 PMID:18328370
- Price D. Asthma and allergic rhinitis : linked in treatment and outcomes. *Ann Thorac Med* 2010, 5: 63-4.
- Tinana A.M, Bloemaum M, Grant A. Managing allergic rhinitis: the role of pharmacotherapy. *Drug Benefit Trends* 2009, 21:312-318.
- Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. *Ann Allergy Asthma Immunol* 2003, 90:416-21. doi:10.1016/S1081-1206(10)61826-1
- Murphy KR. Allergic rhinitis in children: selecting an intranasal corticosteroid. *Ped Asthma Allergy Immunol*, 2005, 18 (4):216-28. doi:10.1089/pai.2005.18.216
- Naclerio R. Clinical manifestations of the release of histamine and the other inflammatory mediators. *J Allergy Clin Immunol* 1999, 103:5382-5385. doi:10.1016/S0091-6749(99)70216-2
- Christoudopoulos P, Cameron L, Durham S, Hamel R. Molecular pathology of allergic disease: Upper airway diseases. *J Allergy Clin Immunol* 2000, 105:211-223. doi:10.1016/S0091-6749(00)90068-X
- Venge P. Monitoring of allergic inflammation. *Allergy* 2004, 59:26-32. doi:10.1046/j.1398-9995.2003.00386.x PMID:14674929
- Lampinen M, Carlson M, Hakansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. *Allergy* 2004 58(8):793-805. doi:10.1111/j.1398-9995.2004.00469.x PMID:15230810
- Minshall E, Ghaffar O, Cameron L, O'Brien F, Quinn J, et al. Assessment by nasal biopsy of long term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. *Otolaryngol Head Neck Surg* 1998, 118(5):648-54. PMID:9591864
- Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. *Arzneimittelforschung* 1998, 48:956-960
- Ciprandi G, Tosca MA, Passalacqua G, Canonica W. Intranasal mometasone furoate reduces late phase inflammation after allergen challenge. *Ann All Asthma Immunol* 2001, 86(1):433-38. doi:10.1016/S1081-1206(10)62491-X
- Bousquet J. Requirements for medications commonly used in the treatment of allergic rhinitis. *Allergy* 2003 58:192-197 doi:10.1034/j.1398-9995.2003.00054.x PMID:12653792
- Berkowitz RB, Bernstein DL, Laforce C, Pedinoff AJ, Rooklin Ar et al. Onset of action of mometasone furoate nasal spray (Nasonex) in seasonal allergic rhinitis. *Allergy* 1999, 54 :64-69. doi:10.1034/j.1398-9995.1999.00713.x PMID:10195359
- Meltzer EO, Tripathy I, Lee J, Lim J, Ellseotr A, Philpot E. Once daily fluticasone furoate nasal spray provides 24 hour relief of nasal symptoms of seasonal allergic rhinitis in children ages 2 -11 years. *J All Clin Immunol* 2007 119(1) abstracts S 305.
- Pitsios C, Papadopoulos D, Kompoti E, Manoussakis E, Garriss V et al. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate to severe seasonal allergic rhinitis. *Ann All Asthma Immunol* 2006, 96:673-78. doi:10.1016/S1081-1206(10)61064-2
- Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate in short term bone growth and HPA axis in children with allergic rhinitis. *Ann Allergy Asthma Immunol* 2003, 90: 56-62. doi:10.1016/S1081-1206(10)63615-0
- Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. *Pediatrics* 2000, 105:E22. doi:10.1542/peds.105.2.e22 PMID:10654982
- Galant SP, Melamed IR, Nayak AS, Blake KV, Prillaman BA et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic pituitary adrenal axis in 2 and 3 year old patients. *Pediatrics* 2003, 112(1): 96-100. doi:10.1542/peds.112.1.96 PMID:12837873
- Gradman J, Caldwell M, Wolthers O D. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray in short term growth in children with allergic rhinitis. *Clin Ther* 2007, 29(8):1738-47. doi:10.1016/j.clinthera.2007.08.017 PMID:17919555
- Dibidox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. *J All Clin Immunol* 2001, 108 (1): 554-58.